Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin
Autore:
Sigthorsson, G; Crane, R; Simon, T; Hoover, M; Quan, H; Bolognese, J; Bjarnason, I;
Indirizzi:
Guys Kings St Thomas Med Sch, Dept Med, London SE5 9PJ, England Guys KingsSt Thomas Med Sch London England SE5 9PJ don SE5 9PJ, England Merck Res Labs, Dept Clin Res, W Point, PA USA Merck Res Labs W Point PA USA k Res Labs, Dept Clin Res, W Point, PA USA
Titolo Testata:
GUT
fascicolo: 4, volume: 47, anno: 2000,
pagine: 527 - 532
SICI:
0017-5749(200010)47:4<527:CIWRDN>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; CYCLOOXYGENASE-2; ASPIRIN; MK-0966; HUMANS; DAMAGE;
Keywords:
rofecoxib; COX-2 inhibitor; indomethacin; non-steroidal anti-inflammatory drugs; intestinal permeability; osteoarthritis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Bjarnason, I Guys Kings St Thomas Med Sch, Dept Med, Bessemer Rd, London SE5 9PJ, England Guys Kings St Thomas Med Sch Bessemer Rd London England SE5 9PJ
Citazione:
G. Sigthorsson et al., "COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin", GUT, 47(4), 2000, pp. 527-532

Abstract

Background-Acute and chronic use of non-steroidal anti-inflammatory drugs can increase intestinal permeability. Rofecoxib, which selectively inhibitscyclooxygenase 2 (COX-2), is a novel antiinflammatory drug with the potential to produce minimal gastrointestinal toxic effects while retaining clinical efficacy. Aims-To assess the potential for rofecoxib to affect the intestine adversely, in comparison with placebo and indomethacin. Subjects-Thirty nine healthy subjects (aged 24-30 years). Method-We performed a four period crossover trial to assess intestinal permeability before and after seven days of treatment. Permeability was measured by the urinary ratio of chromium-51 labelled ethylene diamine tetraacetate ((51)CrEDTA)/L-rhamnose (five hour collection). Results-Indomethacin 50 mg three times daily produced greater increases inintestinal permeability compared with placebo or rofecoxib (25 or 50 mg) (p less than or equal to 0.001); rofecoxib was not significantly different from placebo. Mean day 7 to baseline ratios (95% confidence intervals) for (51)CrEDTA/L-rhamnose were 0.97 (0.82, 1.16), 0.80 (0.68, 0.95), 0.98 (0.82,1.17), and 1.53 (1.27, 1.85) for placebo, rofecoxib 25 mg, rofecoxib 50 mg, and indomethacin groups, respectively. Rofecoxib was generally well tolerated. Conclusion-In this study, treatment for one week with indomethacin 50 mg three times daily significantly increased intestinal permeability compared with placebo, while treatment with rofecoxib 25 mg or 50 mg daily did not. The absence of a significant effect of rofecoxib on intestinal permeability at doses at least twice those recommended to treat osteoarthritis was consistent with other studies that have demonstrated little or no injury to the gastrointestinal mucosa associated with rofecoxib therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 18:38:45